RANOLAZINE IN ISCHEMIC HEART DISEASE
<p>Study results of a new anti-anginal drug (an inhibitor of sodium channels — ranolazine) are presented. Indications, contraindications, major clinical trials of the drug in patients with ischemic heart disease are considered.</p>
Main Author: | |
---|---|
Format: | Article |
Language: | English |
Published: |
Столичная издательская компания
2015-12-01
|
Series: | Рациональная фармакотерапия в кардиологии |
Subjects: | |
Online Access: | http://www.rpcardio.ru/jour/article/view/423 |